Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.

Landi L, Chiari R, Tiseo M, D'Incà F, Dazzi C, Chella A, Delmonte A, Bonanno L, Giannarelli D, Cortinovis DL, De Marinis F, Borra G, Morabito A, Gridelli C, Galetta D, Barbieri F, Grossi F, Capelletto E, Minuti G, Mazzoni F, Verusio C, Bria E, Alì G, Bruno R, Proietti A, Fontanini G, Crinò L, Cappuzzo F.

Clin Cancer Res. 2019 Aug 15. pii: clincanres.0994.2019. doi: 10.1158/1078-0432.CCR-19-0994. [Epub ahead of print]

PMID:
31416808
2.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.

Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27.

PMID:
31319983
3.

Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer.

Ciani O, Cucciniello M, Petracca F, Apolone G, Merlini G, Novello S, Pedrazzoli P, Zilembo N, Broglia C, Capelletto E, Garassino M, Nicod E, Tarricone R.

BMJ Open. 2019 Feb 15;9(2):e025483. doi: 10.1136/bmjopen-2018-025483.

4.

Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal.

Pelosi G, Papotti M, Righi L, Rossi G, Ferrero S, Bosari S, Calabrese F, Kern I, Maisonneuve P, Sonzogni A, Albini A, Harari S, Barbieri F, Capelletto E, Catino AM, Cavone D, De Palma A, Fusco N, Lunardi F, Maiorano E, Marzullo A, Novello S, Papanikolaou N, Pasello G, Pennella A, Pezzuto F, Punzi A, Prisciandaro E, Rea F, Rosso L, Scattone A, Serio G.

J Thorac Oncol. 2018 Nov;13(11):1750-1761. doi: 10.1016/j.jtho.2018.07.002. Epub 2018 Jul 7.

PMID:
30249391
5.

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.

Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, Moran S, Castro de Moura M, Davalos V, Piñeyro D, Sanchez-Cespedes M, Girard N, Brevet M, Giroux-Leprieur E, Dumenil C, Pradotto M, Bironzo P, Capelletto E, Novello S, Cortot A, Copin MC, Karachaliou N, Gonzalez-Cao M, Peralta S, Montuenga LM, Gil-Bazo I, Baraibar I, Lozano MD, Varela M, Ruffinelli JC, Palmero R, Nadal E, Moran T, Perez L, Ramos I, Xiao Q, Fernandez AF, Fraga MF, Gut M, Gut I, Teixidó C, Vilariño N, Prat A, Reguart N, Benito A, Garrido P, Barragan I, Emile JF, Rosell R, Brambilla E, Esteller M.

Lancet Respir Med. 2018 Oct;6(10):771-781. doi: 10.1016/S2213-2600(18)30284-4. Epub 2018 Aug 9.

6.

NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.

Gregorc V, Cavina R, Novello S, Grossi F, Lazzari C, Capelletto E, Genova C, Salini G, Lambiase A, Santoro A.

Oncologist. 2018 Oct;23(10):1133-e112. doi: 10.1634/theoncologist.2018-0292. Epub 2018 Aug 3.

7.

Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.

Kopecka J, Salaroglio IC, Righi L, Libener R, Orecchia S, Grosso F, Milosevic V, Ananthanarayanan P, Ricci L, Capelletto E, Pradotto M, Napoli F, Di Maio M, Novello S, Rubinstein M, Scagliotti GV, Riganti C.

Lung Cancer. 2018 Jun;120:34-45. doi: 10.1016/j.lungcan.2018.03.022. Epub 2018 Mar 26.

PMID:
29748013
8.

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

Metro G, Passaro A, Lo Russo G, Bonanno L, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere FL, Giannarelli D, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Soto Parra H, Rebonato A, Morabito A, Chiari R.

Future Oncol. 2018 Feb;14(4):353-361. doi: 10.2217/fon-2017-0441. Epub 2017 Nov 14.

PMID:
29135281
9.

Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease.

Capelletto E, Rapetti SG, Demichelis S, Galetta D, Catino A, Ricci D, Moretti AM, Bria E, Pilotto S, Bruno A, Valmadre G, Bandelli GP, Trisolini R, Gianetta M, Pacchiana MV, Vallone S, Novello S.

Clin Respir J. 2018 Mar;12(3):1150-1159. doi: 10.1111/crj.12644. Epub 2017 May 10.

PMID:
28466511
10.

Targeted therapy in small cell lung cancer: A new era?

Capelletto E, Mariniello A, Novello S.

Lung Cancer. 2017 Jun;108:252-253. doi: 10.1016/j.lungcan.2017.03.004. Epub 2017 Mar 12. No abstract available.

PMID:
28343730
11.

Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey.

Pacchiana MV, Capelletto E, Carnio S, Gridelli C, Rossi A, Galetta D, Montagna ES, Bordi P, Ceribelli A, Cortinovis D, Scotti V, Martelli O, Valmadre G, Del Conte A, Miccianza A, Morena R, Rosetti F, Di Maio M, Ostacoli L, Novello S.

Clin Lung Cancer. 2017 Jul;18(4):381-387. doi: 10.1016/j.cllc.2016.10.002. Epub 2016 Nov 22.

PMID:
27965013
12.

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

Bersanelli M, Minari R, Bordi P, Gnetti L, Bozzetti C, Squadrilli A, Lagrasta CA, Bottarelli L, Osipova G, Capelletto E, Mor M, Tiseo M.

J Thorac Oncol. 2016 Oct;11(10):e121-3. doi: 10.1016/j.jtho.2016.05.019. Epub 2016 May 31. No abstract available.

13.

Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice.

Novello S, Capelletto E, Cortinovis D, Tiseo M, Galetta D, Valmadre G, Casartelli C, Rapetti SG, Rossi A.

Transl Lung Cancer Res. 2014 Jun;3(3):173-80. doi: 10.3978/j.issn.2218-6751.2014.06.10.

14.

Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome.

Righi L, Vavalà T, Rapa I, Vatrano S, Giorcelli J, Rossi G, Capelletto E, Novello S, Scagliotti GV, Papotti M.

J Thorac Oncol. 2014 Oct;9(10):1540-6. doi: 10.1097/JTO.0000000000000271.

15.

First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era.

Capelletto E, Novello S, Scagliotti GV.

Future Oncol. 2014 May;10(6):1081-93. doi: 10.2217/fon.13.247. Review.

16.

Emerging new agents for the management of patients with non-small cell lung cancer.

Capelletto E, Novello S.

Drugs. 2012 Jun 19;72 Suppl 1:37-52. doi: 10.2165/1163028-S0-000000000-00000. Review.

PMID:
22712796
17.

Updated clinical information on multitargeted antifolates in lung cancer.

Scagliotti GV, Ceppi P, Capelletto E, Novello S.

Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40. doi: 10.3816/CLC.2009.s.006. Review.

PMID:
19362945
18.

Fetal adenocarcinoma of the lung in a 25-year-old woman.

Longo M, Levra MG, Capelletto E, Billè A, Ardissone F, Familiari U, Novello S.

J Thorac Oncol. 2008 Apr;3(4):441-3. doi: 10.1097/JTO.0b013e318169cd9a.

Supplemental Content

Loading ...
Support Center